Quan Zhou
CIK 1491503 · last filed 2025-06-10
Quan Zhou is a corporate insider who has filed 11 SEC Form 4 insider transactions across 3 companies since 2011. The most recent filing, for CRCL, was dated Jun 10, 2025. Across all open-market trades the lifetime net is −$409.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.55B across reported positions. 6 SEC filings were submitted jointly with IDG-Accel China Growth Fund II Associates L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CRCL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
UNIT 1509, THE CENTER, 99 QUEEN'S RD
CENTRAL, K3 -
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRCL | 10%+ Owner | 19,578,183 | $79.00 | $1.55B | -$409.11M | 1 | 2025-06-10 |
| CASI Pharmaceuticals, Inc. (CASI) Delisted | Director | — | $0.28 | — | $0 | 7 | 2022-05-26 |
| MEMSIC Inc (BCDS) Delisted | Director | 55,657,805 | — | — | $0 | 2 | 2012-03-05 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-10 | CRCL | Mixed | +117,099,234 | -$409.11M | EDGAR |
| 2022-05-26 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-16 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-18 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-21 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-07-03 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-09 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-03 | CASI Pharmaceuticals, Inc. (CASI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-09-20 | — | Mixed | −4,765,223 | -$169.0K | |
| 2012-03-05 | MEMSIC Inc (BCDS) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.